RU2097041C1 - Method of diabetes mellitus treatment - Google Patents

Abstract

FIELD: medicine, endocrinology. SUBSTANCE: invention relates to methods of carbohydrate metabolism correction in patients with insulin-dependent and insulin-independent diabetes mellitus. Method involves addition of monosugars in food diet - D-mannose, L-fucose or their mixture at amount 0.05-1 g in pure form or syrup, tablet after eating at condition of milk and dairy products restriction in the diet. EFFECT: accelerated and enhanced effectiveness of treatment.

Description

 The invention relates to medicine, namely endocrinology, in particular (EDI) and non-insulin-dependent (ADDM) diabetes mellitus.

 The invention solves the problem of accelerating the treatment of patients with IDD and IDA, as well as eliminating the dysfunction of the body caused by these diseases due to the correction of carbohydrate metabolism in patients.

 Known methods for the correction of carbohydrates in patients with diabetes mellitus using a diet. To accelerate the correction process, it is proposed to introduce into the diet water extracts of non-glucose base polysaccharides from various plants or their mixtures (ed. St. USSR N 1456156, class A 611 K 35/78, 02/07/89. Bull. N 5; ed. St. USSR N 1697820, class A 61 K 35/78, 12/15/91, bull.

However, such high molecular weight sugars are not hydrolyzed or partially hydrolyzed by amylases of the human digestive tract, and bifidoflora, which is able to hydrolyze 1-2, 1-3 and 1-4 beta-carbohydrate bonds of polysaccharides, is broken in patients with diabetes. (Kuvaeva IB The metabolism of the body and intestinal microflora. M. Medicine, 1976, p. 248). As a result, other monosaccharides necessary for building the immune system and cell membranes, blood specificity groups, and other glycoproteins and glycolipids (White A. et al. Fundamentals of Biochemistry, M. Mir, t. 3, 1981, p. 1878)
As a result of a decrease in the blood of a patient with diabetes mellitus, fucose, mannose, the body is forced to inject glucose, galactose into glycoproteins and glycolipids, which violates the composition of glycoproteins and glycolipids, in particular hemoglobin HB A _Ic (Galenok V.A. et al. Glycosylated proteins. Novosibirsk : Science, 1989.), which is the basis for the diagnosis of non-insulin-dependent diabetes.

 Attempts to correct the diet of patients with diabetes mellitus also show that the rejection of carbohydrate foods worsens the condition of the body and accelerates the appearance of pathology. If at first the diet of patients with diabetes completely excluded carbohydrates, in the 70s it was allowed to introduce polysaccharides into the diet with the exclusion of monosugars, recently, patients with diabetes are allowed to eat foods high in monosugars (fruits, vegetables, honey, etc.). However, this still did not lead to a significant improvement in the condition of patients with diabetes mellitus and a decrease in the manifestation of this disease, but, on the contrary, to an increase in patients with diabetes and diabetes.

 Closest to the claimed method relates to a method for correcting the carbohydrate composition of patients with insulin-dependent diabetes by administering a dietary supplement of D-chiroinositis, which belongs to the class of monosaccharosols, orally, in the same amounts as vitamins (PCT application N 90/10439, class A 61 K 31/45, 09.20.90.).

 The prototype and the claimed invention have the following similar essential features.

 Introduction to the diet of a patient with diabetes monosugars.

 The disadvantage of the prototype is that the introduction of D-chiroinositis into the diet of a patient contributes to the treatment of patients only with ED, the speed and effectiveness of treatment are insufficient, the treatment method does not eliminate the dysfunctions of the patient's body.

 These disadvantages are due to the fact that the method does not allow to completely correct the carbohydrate metabolism in patients with ED, since the injected substance is not a necessary component in the synthesis of glycoproteins and glycolipids.

 The aim of the invention is to accelerate and increase the effectiveness of treatment of patients with IDD and IDD due to the correction of carbohydrate metabolism in patients.

 This goal is achieved by the fact that an additive, D-mannose, L-fucose or a mixture in the amount of 0.05-1.0 g in its pure form or in the form of syrups, tablets after meals with the restriction of milk and products of its processing (except butter).

 In practice, the method is as follows. After taking breakfast, consisting, for example, of oatmeal, tea with bread and butter, 0.3-0.5 g of D-mannose or 0.3-0.5 g of L-fucose in the form of a powder, or their mixture in the form of a powder, tablet or syrup. 20 minutes after taking the carbohydrate supplement, an increase in salivation in patients with diabetes mellitus was noted, and after 2 hours, improvement in well-being in patients with diabetes and after 2-3 days in patients with diabetes.

 The increase in salivation in patients with diabetes mellitus is associated with the absorption of these sugars in the oral cavity and their entry into the salivary glands, where the synthesis of mucopolysaccharides, which require mannose and fucose in human blood for synthesis, is accelerated.

 Improving the well-being of patients with diabetes after 2 hours after taking a carbohydrate supplement is associated with the release of proinsulin from the beta cell and the withdrawal of the C peptide and insulin from the beta cell (White A. et al. General Biochemistry. M. Mir, vol. 3, 1981 p. 1634), requiring a vesicle for insulin withdrawal, which has surface receptor glycoproteins, which require D-mannose for their synthesis in the Golgi apparatus. The removal of insulin from the beta cell helps to reduce the exogenous insulin administered to patients with ED.

 Improving the well-being of patients with ADHD after 2-3 days is due to the fact that the synthesis of insulin in beta cells is normal, but it can enter a cell (for example, the liver) only if receptors consisting of glycoproteins are located on the cell surface ( White A. et al. General Biochemistry, M. Mir, vol. 3, 1981, p. 1638). In patients with ADHD, glycoproteins are impaired due to the absence of D-mannose and / or L-fucose in the blood of a sick person, which was established by analysis of blood sugars by gas chromatography, and therefore receptor glycoproteins are either not synthesized or abnormal in composition. Therefore, with the introduction of D-mannose, L-fucose into the human body, normal cells with receptors from normal glycoproteins begin to be synthesized and insulin is injected into cells resistant to it and glycogen accumulation is carried out.

 The restriction in the diet of diabetes patients with dairy products is due to the fact that cow's milk, unlike female milk, does not contain fucose-containing oligosaccharides (Stepanenko BN Chemistry and biochemistry of carbohydrates (polysaccharides). M. Higher School, 1978, p. 31) and for the correction of carbohydrate metabolism, along with D-mannose and L-fucose, which are introduced specifically, the intake of these sugars along with carbonaceous food is required. Such a correction is necessary to restore over time all carbohydrate metabolism in the human body and after stopping the intake of D-mannose, L-fucose, the body itself could absorb these sugars from food and partially synthesize it by the metabolic pathway. When dairy products are taken in the form of a carbohydrate component, L-fucose and its derivatives cannot enter the body and, accordingly, carbohydrate metabolism will again be disturbed, which will again lead to the manifestation of EDI or ADI.

 The possibility of implementing the proposed method using the full totality of the claimed features is confirmed by examples of specific treatment of patients with EDI and IDA.

 Example 1. Patient J. 50 years. Diagnosis: diabetes mellitus type moderate disability, stage of decompensation. Glycemic profile before treatment: 8-12.3; 12-11.1; 17-13.5 mmol / L. In addition to taking 0.05 g of L-fucose 10 minutes after a meal, no corrective therapy and sugar-lowering drugs were taken. As a result of the treatment, the patient notes an increase in working capacity and an improvement in the psychoemotional background, a decrease in fatigue and drowsiness, an improvement in vision, faster than usually the symptoms of acute respiratory viral infections that occur during treatment have disappeared. The glycemic profile at the end of the 30-day treatment is 8-3.9; 12-5.2; 17-4.8 mmol / L.

 Example 2. Patient G. 40 years. Diagnosis: diabetes type INZD severe course, stage of decompensation. The duration of the disease is 3 years. Glycemic profile before treatment: 8-8.6; 12-9.7; 17-7.3 mmol / L.

 On the second day of taking 1.0 per day, 30 minutes after eating D-mannose, symptoms of hypoglycemia were clinically and laboratory observed. The daily dose of insulin was reduced by 6 units, which led to the stabilization of the state. However, on the 4th day of taking the drug, symptoms of mild hypoglycemia reappeared, which caused a decrease in the dose of insulin by 2 more units. During the administration of D-mannose, the patient stabilized sleep, improved skin firmness and elasticity. Glycemic profile after treatment: 8-4.2; 12-5.7; 17-6.5 mmol / L.

 Example 3. Patient S. 27 years. Diagnosis: diabetes mellitus type INZD severe labile course, decompensation stage. The duration of the disease is 18 years. As a result of a mixture of 0.25 g of L-fucose and 0.25 g of D-mannose, 120 min after eating with traditional insulin therapy, a gradual positive dynamics was observed during the disease: general weakness decreased, activity increased, stool stabilized (pre-treatment prevailed constipation), the level of glycemia decreased. Glycemic profile before treatment: 8-18,0; 12-12.8; 17-12.8 mmol / l, after a course of treatment: 8-7.0; 12-7.41; 17-8.2 mmol / L.

 Example 4. Patient K., 26 years old. Diagnosis: diabetes mellitus type IZD, severe labile course, stage of decompensation with ketosis. Diabetes suffers for 6 years.

 Glycemic profile before treatment: 8-15.2; 12-20.0; 17-10.1 mmol / L. The patient took 3 times a day after eating 1 ml of a solution of 50% containing 0.1 g of L-fucose and 0.1 g of D-mannose. 2 hours after taking the first dose of the drug, the patient felt improved health, vitality and increased tone. During treatment, according to the results of laboratory and clinical observations, the total daily dose of insulin was reduced by 12 units. As a result of the therapy, acstopuria was achieved, and manifestations of diabetic encephalopathy in the form of improved memory and headaches were reduced. A trophic ulcer 5x7 mm in size was healed on the dorsum of the forearm of the right hand.

 Glycemic profile after treatment: 8-7.2; 12-9.4; 17-8.6 mmol / L.

 As shown by experimental data, the claimed limits of the method parameters are due to the fact that, when the amount of monosaccharides introduced into the diet is reduced to less than 0.05 g, it does not create the necessary conditions for a sufficient synthesis of glycoproteins and glycolipids, but an increase in the dose of introduced preparations of more than 1 g is impractical because the amount of monosugar is enough to achieve the goal.

 Thus, the invention is feasible, its use in medicine will not only increase the effectiveness of treatment of patients with diabetes, but also to adjust the carbohydrate metabolism in the patient’s body, which helps to prevent many disorders of the body’s functions.

Claims (1)

 A method for the treatment of diabetes mellitus, comprising introducing monosaccharides into a patient’s diet, characterized in that D-mannose, L-fucose or a mixture thereof in an amount of 0.05 1 g in pure form or in the form of syrups, tablets after meals are used as monosugars with the restriction of milk and its processed products.